Nsgene A/s

Gloriana Therapeutics Sarl

Hoba Therapeutics Aps

Gloriana Therapeutics, Inc.

Nsgenee A/s

Lars Ulrik Wahlberg

Teit E Johansen

Philip Kusk

Jesper Roland Jorgensen

Lone Fjord-Larsen

Nuno Miguel Gomes Andrade

Jesper Roland Jørgensen

Jens Tornøe

Nuno Miguel Andrade

Jens Tornoe

The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Cell lines and their use in encapsulated cell biodelivery

The invention comprises an implantable cell device that includes a membrane defining and enclosing a chamber; a distance body within the chamber for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold within the chamber for increasing the cell support surface area per unit volume of the chamber for distributing cells.

Implantable cell device with supportive and radial diffusive scaffolding

The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.

Therapeutic use of a growth factor, METRNL

The present invention relates to use of Cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia. The Cometin polypeptide may be delivered as a polypeptide or by administration of an expression vector for expression of Cometin, a cell line transformed or transduced with said vector and a capsule comprising said cells.

Treatment of hyperalgesia, spontaneous pain, and phantom pain

The invention features an implantable cell device. The device includes a membrane defining and enclosing a chamber; a distance body, within the chamber, for reducing the diffusion distance for a biological active factor to or across the membrane; and a support scaffold, within the chamber, for increasing the cell support surface area per unit volume of the chamber for distributing cells.

Treatment of allodynia

The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.

Growing community of inventors

Tiverton, RI, United States of America

Lars Ulrik Wahlberg